Polyarteritis Nodosa: ['A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative. [ NCI ]']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
87 |
4. Check minimum number of eventsNone |
87 |
5. Include endpointsNone |
87 |
6. Filter based on genotype QC (FinnGen only) |
87 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Aliae condiciones polyarteritidi nodosae cognatae
Similar endpoints
↥List of similar endpoints to
Other conditions related to polyarteritis nodosa
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 581 | 336 | 240 |
| Only index persons | 484 | 287 | 197 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.23 | 64.19 | 64.15 |
| Only index persons | 62.10 | 63.01 | 60.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 87 | 54 | 33 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 57.75 | 54.01 | 63.87 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 82
- Matched controls
- 821
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
112.5
80
*
H02AB06
ATC
prednisolone; systemic
21.3
24.9
75
274
L04AX01
ATC
azathioprine; systemic
33.8
20.2
26
11
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
18.4
17
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
12.1
16.1
31
39
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.8
14.9
54
180
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.5
10.1
18
18
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
7.8
10.1
24
41
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.6
9.9
54
241
M05BA04
ATC
alendronic acid; oral
8.7
9.6
21
31
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
12.9
9.3
16
15
H02AB07
ATC
prednisone; oral
6.0
8.6
25
56
M31.7
ICD-10 Finland
Microscopic polyangiitis
+∞
8.5
8
*
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
8.5
8
*
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
8.5
8
*
PAW37
NOMESCO Finland
Biopsy of temporal artery
+∞
8.5
8
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.5
8.4
35
116
H02AB09
ATC
hydrocortisone; systemic
25.1
8.3
11
5
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.1
7.3
20
41
N03AX16
ATC
pregabalin; oral
4.0
7.3
34
123
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.1
6.9
15
22
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
10.1
6.9
13
15
TAB00
NOMESCO Finland
Lumbar puncture
10.6
6.5
12
13
UDH02
NOMESCO Finland
Rhinopharyngoscopy
7.4
6.5
15
24
R50.9
ICD-10 Finland
Fever, unspecified
5.1
6.5
21
52
ZX120
NOMESCO Finland
Intravenous
5.1
6.5
21
52
D69.0
ICD-10 Finland
Allergic purpura
29.2
6.4
8
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
6.3
6
*
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
+∞
6.3
6
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
+∞
6.3
6
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
16.6
6.1
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
17
30.66
44.58
4.0
1.5
242.9
—
titre
—
7
0
24
14
23.29
30.10
8.9
1.3
14.0
—
iu/ml
—
8
0
18
14
15.95
19.15
3.6
1.4
—
—
—
0
0
11
10
12.45
10.37
1.3
1.3
—
—
—
0
0
53
231
4.31
10.29
7.0
2.9
—
—
—
0
0
11
11
11.30
9.74
2.2
1.5
—
—
—
0
0
11
11
11.30
9.74
1.8
1.2
—
—
—
0
0
62
333
4.00
8.29
8.7
8.4
1.2
1.2
mmol/l
0.45
52
287
10
11
10.14
8.25
1.2
2.0
—
—
—
0
0
10
12
9.29
7.74
1.2
1.9
—
—
—
0
0
31
115
3.63
7.15
2.3
1.8
—
—
—
0
0
22
68
3.99
6.54
3.3
1.9
240.8
403.6
nmol/l
3.13
22
58
51
270
3.15
6.42
8.3
3.6
27.2
47.1
ng/l
0.67
40
183
9
5
19.81
6.41
1.8
1.2
—
—
—
0
0
32
132
3.25
6.13
1.7
1.6
1.3
1.1
mg/l
0.21
24
109
10
9
12.35
5.96
1.2
2.2
—
—
—
0
0
10
17
6.52
5.77
1.5
1.6
—
—
—
0
0
10
17
6.52
5.77
1.5
1.6
—
—
—
0
0
16
46
4.04
5.18
6.3
5.2
1.2
1.2
mmol/l
0.20
16
41
9
10
9.87
4.91
1.2
2.0
—
—
—
0
0
37
185
2.74
4.86
7.6
2.7
0.1
0.4
e6/l
1.71
32
146
63
416
2.86
4.69
5.9
6.0
6.9
6.7
mmol/l
0.17
63
389
11
26
4.70
4.50
1.9
2.6
—
—
—
0
0
35
177
2.64
4.43
3.3
2.7
342.9
7295.0
umol/l
1.06
30
145
57
366
2.62
4.36
7.1
3.4
0.0
0.0
estimate
0.00
20
72
24
102
2.87
4.21
2.0
1.7
29.7
29.2
s
0.19
24
97
12
33
4.06
4.08
3.2
8.7
24.0
25.4
mmol/l
0.74
12
33
21
86
2.90
3.92
2.1
1.6
—
—
—
0
0
6
5
12.74
3.82
1.3
2.0
—
—
—
0
0
56
372
2.42
3.76
7.2
3.4
0.0
0.0
estimate
0.00
22
70
55
365
2.38
3.66
9.7
4.6
0.0
0.0
estimate
0.00
22
72
11
31
3.92
3.61
2.7
1.5
—
—
—
0
0
25
118
2.57
3.54
1.5
1.2
44.3
49.5
iu/ml
—
10
39
38
218
2.32
3.52
7.1
3.5
0.0
0.0
estimate
0.00
22
66
7
12
6.23
3.08
1.7
1.8
—
—
—
0
0
23
111
2.46
3.08
1.4
1.2
41.8
25.4
u/ml
—
9
41
13
46
3.15
3.07
3.5
2.9
72.9
66.4
ng/l
0.12
13
41
19
84
2.61
3.04
2.2
1.5
—
—
—
0
0
47
310
2.12
2.96
4.1
2.3
322.8
110.0
ug/l
0.63
47
285
7
13
5.75
2.93
1.7
1.6
—
—
—
0
0
7
14
5.33
2.79
2.4
1.8
—
—
—
0
0
5
6
8.74
2.78
2.0
1.7
—
—
—
0
0
5
7
7.49
2.58
2.0
1.6
—
—
—
0
0
13
51
2.82
2.58
2.5
1.6
—
—
—
0
0
17
77
2.50
2.58
4.7
3.4
—
—
—
0
0
5
8
6.54
2.40
1.4
1.0
—
—
—
0
0
5
9
5.81
2.24
2.4
4.7
—
—
—
0
0
6
15
4.21
2.07
1.5
1.4
—
—
—
0
0
6
15
4.21
2.07
1.5
1.4
—
—
—
0
0
8
26
3.28
2.07
1.1
1.0
—
—
—
0
0
5
12
4.35
1.85
1.0
2.0
—
—
—
0
0
8
29
2.93
1.84
1.6
1.3
—
—
—
0
0
24
145
1.90
1.78
2.4
2.5
—
—
—
0
0
45
334
1.72
1.68
5.6
4.5
—
—
—
0
0
19
108
1.97
1.67
7.2
2.6
3.5
3.7
e6/l
0.03
12
67
6
20
3.14
1.61
1.0
1.0
35.8
38.2
g/l
—
6
15
6
20
3.14
1.61
1.2
1.3
—
—
—
0
0
38
274
1.69
1.55
2.1
1.8
99.5
95.6
pmol/l
0.22
18
132
5
15
3.47
1.54
1.8
1.6
—
—
—
0
0
40
296
1.65
1.46
7.7
3.5
—
—
—
0
0
15
83
1.98
1.42
9.3
7.5
—
—
—
0
0
8
34
2.49
1.33
1.5
1.6
—
—
—
0
0
6
24
2.61
1.33
2.5
2.0
—
—
—
0
0
6
24
2.61
1.33
2.8
2.2
—
—
—
0
0
23
156
1.64
1.14
1.2
1.3
0.6
0.8
u/ml
—
6
37
18
115
1.71
1.10
7.3
2.4
0.5
1.1
e6/l
0.70
11
71
72
640
1.73
1.09
5.3
4.7
2.0
1.9
mu/l
0.19
66
577
73
652
1.74
1.08
32.5
13.4
82.2
81.1
ml/min/173m2
0.14
67
519
51
447
1.34
0.62
4.5
3.1
69.0
49.6
u/l
0.87
46
421
25
197
1.38
0.60
4.8
4.8
2.5
1.9
ug/l
0.53
20
175
50
439
1.33
0.59
4.1
3.1
—
—
—
0
0
11
77
1.49
0.48
2.9
2.3
—
—
—
0
0
70
656
1.34
0.45
4.4
4.0
1.4
1.3
mmol/l
0.99
65
597
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
11
83
1.37
0.34
3.6
2.6
—
—
—
0
0
6
46
1.33
0.34
5.0
2.2
667.5
154.0
ng/l
—
6
41
71
678
1.26
0.29
4.6
4.4
1.5
1.5
mmol/l
0.41
66
618
18
155
1.20
0.22
3.6
4.2
20.3
21.4
%
—
10
77
0
10
0.00
0.21
0.0
5.7
—
174.5
—
0
10
15
129
1.20
0.18
1.6
1.5
—
—
—
0
0
72
698
1.18
0.17
4.9
4.9
2.6
2.7
mmol/l
0.76
67
639
10
118
0.83
0.15
1.2
1.5
—
—
—
0
0
69
684
1.04
0.00
5.9
4.5
5.8
5.9
mmol/l
0.23
63
618
0
6
0.00
0.00
0.0
1.2
—
3.9
—
0
6
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
25.1
—
0
6
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_POYARTOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.789 [2.0, 3.89] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.129 |
During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 272 females with M13_POYARTOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.272 [1.53, 3.36] | < 0.001 |
| Birth year | 0.986 [0.97, 1.0] | 0.026 |
During the follow-up period (1.1.1998 — 31.12.2019), 72 out of 194 males with M13_POYARTOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_POYARTOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.244% | 0.365% |
| 5 | 1.567% | 2.344% |
| 10 | 4.319% | 5.549% |
| 15 | 7.846% | 11.556% |
| 20 | 13.131% | 19.031% |
Relationships between endpoints
↥Index endpoint: M13_POYARTOTH – Other conditions related to polyarteritis nodosa
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data